Audentes therapeutics, inc. (BOLD)
CashFlow / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net loss

-45,741

-44,764

-49,391

-35,592

-36,291

-31,367

-25,571

-24,375

-25,009

-22,739

-18,115

-19,676

-15,369

-14,159

-10,464

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,000

2,000

1,700

1,695

1,500

1,251

1,149

988

909

769

732

698

643

211

78

Amortization of right-of-use assets

718

668

580

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

5,712

6,131

5,500

4,380

4,633

4,097

3,385

2,827

1,530

1,468

1,055

698

599

380

327

Accretion of discount on marketable securities

838

950

1,090

1,005

510

225

121

176

112

37

25

151

-37

-32

-133

Accretion of asset retirement obligation

-

-

-

-

-

-

-

-

-

-

-

5

11

8

82

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

57

80

-22

29

16

-59

-2,284

103

-4

74

90

-194

114

92

90

Other

-6

-9

-6

-472

-50

1

-34

-65

-109

-110

-53

-5

0

-35

-31

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-4,196

4,708

0

Prepaid expenses and other current assets

-824

2,047

-1,814

938

-355

1,842

-275

-301

193

292

491

-2,176

-3,707

3,396

1,402

Other assets

-

-

-

-

-

-

-

12

-20

620

1,400

41

0

-68

0

Accounts payable

1,298

-3,080

1,852

4,805

-515

-805

596

-525

571

1,870

-1,230

400

142

1,110

-2,323

Accrued liabilities

752

3,440

-2,644

-2,618

2,788

4,070

-2,223

-32

-737

2,219

-3,029

3,597

207

1,461

-450

Deferred rent

0

0

0

-287

355

-1,519

-168

250

60

-1,094

-153

-28

94

-539

-1,049

Operating lease liabilities

-802

-757

-553

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-35,873

-40,824

-42,220

-28,483

-31,551

-23,352

-24,592

-23,298

-22,976

-16,084

-22,207

-11,943

-5,807

-18,327

-12,849

Purchases of property and equipment

4,376

4,353

1,288

3,535

2,704

4,449

921

2,520

2,814

1,465

752

2,294

5,512

6,700

2,145

Proceeds from maturities of marketable securities

124,398

110,151

146,802

80,706

48,000

45,105

34,775

43,300

34,518

17,000

32,010

14,827

21,454

5,114

17,229

Purchases of marketable securities

131,791

146,824

117,488

172,073

125,154

49,504

35,294

35,339

46,498

44,446

26,430

51,224

10,781

27,376

14,656

Net cash used in investing activities

-11,769

-41,026

28,026

-94,902

-79,858

-8,848

-1,440

5,441

-14,794

-28,911

4,828

-38,690

5,161

-28,947

428

Proceeds from exercise of stock options and ESPP purchases

4,147

2,203

3,000

850

1,253

1,139

807

185

282

227

134

15

49

17

76

Proceeds from issuance of common stock, net of issuance costs

8,328

46,045

0

162,689

0

14,602

217,122

2,702

36,445

80,578

0

-

-

-

-

Net cash provided by financing activities

12,237

47,685

3,005

163,539

1,253

15,741

217,929

2,887

36,727

80,805

134

15

75,257

17

76

Net (decrease) increase in cash, cash equivalents and restricted cash

-35,405

-34,165

-11,189

40,154

-110,156

-16,459

191,897

-14,970

-1,043

35,810

-17,245

-50,618

74,611

-47,257

-12,345

Noncash investing and financing activities:
Change in accounts payable and accrued liabilities related to property and equipment purchases

-1,664

378

3,072

207

185

-278

2,293

81

-1,391

2,043

506

-1,566

-2,664

1,742

3,415

Issuance of common stock warrant related to debt financing facility

-

-

-

-

-

-

-

0

0

0

83

0

0

0

0

Deferred financing costs for follow-on offering

-

-

0

-

-

-

115

0

0

0

0

-

-

-

-

Operating leases

-

-

1,323

-

-

-

-

-

-

-

-

-

-

-

-